

Use of Pneumococcal Vaccines (PPSV23, PCV13) for Adults 19 years and Older

Recommended groups for PPSV23 (Pneumococcal Polysaccharide Vaccine)	PPSV23 Schedule
<p>Vaccinate all persons aged 2-64 years:</p> <ul style="list-style-type: none"> • With chronic cardiovascular disease (including congestive heart failure, cardiomyopathies), chronic pulmonary disease (including COPD and emphysema) or diabetes mellitus • With alcoholism or chronic liver disease (including cirrhosis) • Within environments or settings with identified increased risk • Who have a Cerebral Spinal Fluid (CSF) leak • Who have a cochlear implant 	<p>Persons who are immunocompetent should receive:</p> <ul style="list-style-type: none"> • 1 dose of PPSV23 between the ages of 2-64 years • 1 dose of PPSV23 at/after age 65 years <p>Use a minimum interval of 5 years between PPSV23 doses</p> <p>PCV13 is also indicated for persons with CSF leaks and cochlear implants (see below)</p>
<p>Vaccinate persons aged 2-64 years:</p> <ul style="list-style-type: none"> • With functional or anatomic asplenia (including sickle cell disease and splenectomy) • With immunocompromising conditions including HIV infection, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, generalized malignancy, chronic renal failure or nephrotic syndromes, congenital or acquired immunodeficiencies • Who have diseases with treatment using immunosuppressive drugs, including long-term systemic corticosteroids or radiation therapy • Who have received solid organ transplantation 	<p>Persons with asplenia or who are immunocompromised should receive:</p> <ul style="list-style-type: none"> • 2 doses of PPSV23 between the ages of 2-64 years • 1 dose of PPSV23 at/after age 65 years <p>Use a minimum interval of 5 years between PPSV23</p> <p>PCV13 is also indicated for persons within one of these risk groups (see below)</p>
<p>Vaccinate persons aged 19-64 years:</p> <ul style="list-style-type: none"> • With asthma or who smoke cigarettes 	<p>Persons with one or more of these risk factors should receive:</p> <ul style="list-style-type: none"> • 1 dose of PPSV23 between the ages of 2 -64 years • 1 dose of PPSV23 at/after age 65 years <p>Use a minimum interval of 5 years between PPSV23 doses</p>
<p>Vaccinate all persons aged 65 years and older:</p> <ul style="list-style-type: none"> • Regardless of their medical or risk condition • Regardless of any previous history of receiving PPSV23 	<p>For <u>all</u> persons who are aged 65 years and older:</p> <ul style="list-style-type: none"> • 1 dose of PPSV23 <p>Regardless of current or any changes to medical condition, <u>no</u> additional doses of PPSV23 are recommended after this dose</p> <p>If PPSV23 was given before age 65 years, use a minimum interval of 5 years before giving this final dose</p>
Recommended Groups for PCV13 (Pneumococcal Conjugate Vaccine)	PCV13 Schedule
<p>Vaccinate all persons aged 19 years and older:</p> <ul style="list-style-type: none"> • Who have a CSF leak or cochlear implant • With functional or anatomic asplenia (including sickle cell disease and splenectomy) • With immunocompromising conditions including HIV infection, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, generalized malignancy, chronic renal failure or nephrotic syndromes, congenital or acquired immunodeficiencies • Who have diseases with treatment using immunosuppressive drugs, including long- term systemic corticosteroids or radiation therapy • Who have received solid organ transplantation 	<p>For all persons who are 19 years and older:</p> <ul style="list-style-type: none"> • 1 dose of PCV13¹ <p>Preferred that PCV13 be given before any doses of PPSV23</p> <ul style="list-style-type: none"> • If no previous doses of PPSV23, give PCV13 first & then give PPSV23 at least 8 weeks later (minimum interval) • If one or more doses of PPSV23 have been given, there should be at least 1 year (minimum interval) between the last PPSV23 & the PCV13 dose <p>Continue to use a minimum interval of 5 years between two PPSV23 doses</p>

¹ If a previous dose of PCV13 was given prior to age 19 years, an additional dose at/after age 19 years is not recommended; for PCV13 recommendations for persons aged less than 19 years, refer to: "A Quick Look at Using Prevnar 13™ PCV13)" at www.michigan.gov/immunize

Resources: Use of PCV13 & PPSV23 in Adults with Immunocompromising Conditions, ACIP Recommendations, MMWR 61(40) October 12, 2012; Updated Recommendations for Prevention of Invasive Pneumococcal Disease in Adults using PPSV23, MMWR 59(24) September 10, 2010; Prevention of Pneumococcal Disease, Recommendations of ACIP, MMWR 46(08) April 4, 1997; All available at www.cdc.gov/vaccines